Associations of Plasma Pentraxin 3 and Monocyte Chemoattractant Protein-1 Concentrations with Cardiovascular Disease in Patients with Chronic Kidney Disease

REFERENCES

• Sarnak MJ, Levey AS, Schoolwerth AC, Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation. 2003;108:2154–2169.
   PubMed Web of Science ®Google Scholar
• Roberts MA, Hare DL, Ratnaike S, Ierino FL. Cardiovascular biomarkers in CKD: Pathophysiology and implications for clinical management of cardiac disease. Am J Kidney Dis. 2006;48:341–360.
   PubMed Web of Science ®Google Scholar
• Menon V, Greene T, Wang X, C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int. 2005;68:766–772.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Garlanda C, Doni A, Bottazzi B. Pentraxins in innate immunity: From C-reactive protein to the long pentraxin PTX3. J Clin Immunol. 2008;28:1–13.
   PubMed Web of Science ®Google Scholar
• Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005;23:337–366.
   PubMed Web of Science ®Google Scholar
• Introna M, Alles VV, Castellano M, Cloning of mouse PTX3, a new member of the pentraxin gene family expressed at extrahepatic sites. Blood. 1996;87:1862–1872.
   PubMed Web of Science ®Google Scholar
• Alles VV, Bottazzi B, Peri G, Golay J, Introna M, Mantovani A. Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. Blood. 1994;84:3483–3493.
   PubMed Web of Science ®Google Scholar
• Peri G, Introna M, Corradi D, PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000;102:636–641.
   PubMed Web of Science ®Google Scholar
• Inoue K, Sugiyama A, Reid PC, Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol. 2007;27:161–167.
   PubMed Web of Science ®Google Scholar
• Kotooka N, Inoue T, Fujimatsu D, Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening. Atherosclerosis. 2008;197:368–374.
   Google Scholar
• Suliman ME, Yilmaz MI, Carrero JJ, Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin J Am Soc Nephrol. 2008;3:976–985.
   PubMed Web of Science ®Google Scholar
• Boehme M, Kaehne F, Kuehne A, Pentraxin 3 is elevated in hemodialysis patients and is associated with cardiovascular disease. Nephrol Dial Transplant. 2007;22:2224–2229.
   PubMed Web of Science ®Google Scholar
• Tong M, Carrero JJ, Qureshi AR, Plasma pentraxin 3 in patients with chronic kidney disease: Associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol. 2007;2:889–897.
   PubMed Web of Science ®Google Scholar
• Leonard EJ, Yoshimura T. Human monocyte chemoattractant protein-1 (MCP-1). Immunol Today. 1990;11:97–101.
   PubMedGoogle Scholar
• Rollins BJ, Yoshimura T, Leonard EJ, Pober JS. Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE. Am J Pathol. 1990;136:1229–1233.
   PubMed Web of Science ®Google Scholar
• Sica A, Wang JM, Colotta F, Monocyte chemotactic and activating factor gene expression induced in endothelial cells by IL-1 and tumor necrosis factor. J Immunol. 1990;144:3034–3038.
   PubMed Web of Science ®Google Scholar
• Reape TJ, Groot PH. Chemokines and atherosclerosis. Atherosclerosis. 1999;147:213–225.
   PubMed Web of Science ®Google Scholar
• Hojo Y, Ikeda U, Takahashi M, Shimada K. Increased levels of monocyte-related cytokines in patients with unstable angina. Atherosclerosis. 2002;161:403–408.
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Morrow DA, Sabatine MS, Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. 2003;107:690–695.
   PubMed Web of Science ®Google Scholar
• Stinghen AE, Goncalves SM, Martines EG, Increased plasma and endothelial cell expression of chemokines and adhesion molecules in chronic kidney disease. Nephron Clin Pract. 2009;111:c117–c126.
   Google Scholar
• Papayianni A, Alexopoulos E, Giamalis P, Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in hemodialysis patients: Association with inflammation, dyslipidaemia, and vascular events. Nephrol Dial Transplant. 2002;17:435–441.
   PubMed Web of Science ®Google Scholar
• Imai E, Horio M, Watanabe T, Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol. 2009;13:621–630.
   PubMed Web of Science ®Google Scholar
• Nauta AJ, de Haij S, Bottazzi B, Human renal epithelial cells produce the long pentraxin PTX3. Kidney Int. 2005;67:543–553.
   PubMed Web of Science ®Google Scholar
• Bussolati B, Peri G, Salvidio G, Verzola D, Mantovani A, Camussi G. The long pentraxin PTX3 is synthesized in IgA glomerulonephritis and activates mesangial cells. J Immunol. 2003;170:1466–1472.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Garlanda C, Bottazzi B, The long pentraxin PTX3 in vascular pathology. Vascul Pharmacol. 2006;45:326–330.
   PubMed Web of Science ®Google Scholar
• Bottazzi B, Garlanda C, Salvatori G, Jeannin P, Manfredi A, Mantovani A. Pentraxins as a key component of innate immunity. Curr Opin Immunol. 2006;18:10–15.
   PubMed Web of Science ®Google Scholar
• Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2002;22:e10–e14.
   PubMed Web of Science ®Google Scholar
• Savchenko A, Imamura M, Ohashi R, Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol. 2008;215:48–55.
   PubMed Web of Science ®Google Scholar
• Klouche M, Peri G, Knabbe C, Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis. 2004;175:221–228.
   PubMed Web of Science ®Google Scholar
• Camozzi M, Zacchigna S, Rusnati M, Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo. Arterioscler Thromb Vasc Biol. 2005;25:1837–1842.
   PubMed Web of Science ®Google Scholar
• Napoleone E, Di Santo A, Bastone A, Long pentraxin PTX3 upregulates tissue factor expression in human endothelial cells: A novel link between vascular inflammation and clotting activation. Arterioscler Thromb Vasc Biol. 2002;22:782–787.
   PubMed Web of Science ®Google Scholar
• Egashira K:. Molecular mechanisms mediating inflammation in vascular disease: Special reference to monocyte chemoattractant protein-1. Hypertension. 2003;41:834–841.
   PubMed Web of Science ®Google Scholar
• Gu L, Okada Y, Clinton SK, Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998;2:275–281.
   PubMed Web of Science ®Google Scholar